Define intended use, traceable records, access controls and test evidence without confusing software features with regulatory certification.
Loading the article…
Bring the problem you want solved. We’ll shape it into a project brief you can keep — or let AI draft a first approach.
“Audit-ready” should describe evidence that people can inspect, not a badge attached to a software product. A useful project starts with the intended use, the records involved and the customer’s quality procedures. Controls and validation responsibilities follow from that context.
Identify what the system creates, changes, retains or transfers. Document who relies on those records and which decisions they support. Distinguish an illustrative dashboard from a system authorized to change operational status.
FDA’s Part 11 scope and application guidance explains that applicability depends on the relevant electronic records and underlying requirements. It is not a universal certification label for every application used by a pharmaceutical company.
Translate a phrase such as “maintain an audit trail” into explicit behavior: which events are recorded, which identity is associated with them, how changes are represented and who can inspect the history. Define the required controls with the quality owner.
For access, test the prohibited action as well as the permitted one. Include backend enforcement, not just whether a button is visible. Assess how permissions change when a person’s role changes or access is removed.
For each significant requirement, identify an acceptance check and the evidence it produces. Include invalid inputs, interrupted operations, unauthorized requests and recovery. Document the environment and assumptions so a result can be interpreted later.
A collection of passing unit tests is useful engineering evidence, but it does not by itself establish suitability for every intended use. Operational procedures, configuration and responsibilities also matter.
FDA’s February 2026 Computer Software Assurance guidance addresses software used in medical-device production or the quality management system. Do not present that guidance as a blanket drug-manufacturing requirement. Determine which sources apply to the actual project and product context.
Software can support traceable records, access controls, review workflows and test documentation. It cannot promise automatic compliance or replace the customer’s quality-system decisions.
Explore pharma quality-management development and US project considerations. Bring a redacted procedure and a defined workflow to the discussion; no confidential records are needed in the public project brief.
